Adjuvanted RSVPreF3 can be co-administered with a COVID-19 mRNA vaccine in adults aged ≥50 years

Presented by

Dr Sofia Valenciano , GSK, Belgium

Conference

ESCMID Vaccines 2025

Adjuvanted RSVPreF3 co-administered with a COVID-19 mRNA vaccine was shown to be non-inferior to sequential administration 30 days apart, with acceptable safety and tolerability in adults aged ≥50.

Dr Sofia Valenciano (GSK, Belgium) presented results of a phase 3 (NCT06374394), open-label, randomised (1:1) trial comparing co-administration of adjuvanted RSVPreF3 with a COVID-19 mRNA vaccine to administration of the two vaccines 30 days apart (control) [1]. Adults aged ≥50 years who had received at least 1 COVID-19 vaccine dose ≥3 months prior to study entry were eligible for enrolment. The upper limit of the 2-sided 95% CI of geometric mean titre (GMT) ratios ≤1.50 was set as the non-inferiority success criterion for all three RSV-A, RSV-B, and XBB 1.5 strains assessed. A total of 417 participants received co-administration, while 416 received control.

Co-administration of the two vaccines met the non-inferiority criteria for RSV-A (GMT ratio 1.12; 95% CI 0.97-1.28) and RSV-B (GMT ratio 1.08; 95% CI 0.94-1.23), but the upper limit of the 95% CI for the GMT ratio crossed 1.50 for XBB 1.5 (GMT ratio 1.31; 95% CI 1.13-1.51; see Figure). In terms of safety, there was a trend for injection-site adverse events to be higher in the co-administration group, primarily driven by injection-site pain (72.3% vs. 64.2% at the COVID-19 vaccine site and 73.3% vs. 58.5% at the adjuvanted RSVPreF3 site). No events of neurological demyelinating disorders or deaths were reported, while atrial fibrillation was reported in 1 participant in each group.

Figure. Adjusted GMT ratios at 30 days post-vaccination [1]

Co-Ad, coadministered; GMT, geometric mean titre.

“The study results support co-administration of the adjuvanted RSVPreF3 vaccine with a COVID-19 mRNA vaccine”, concluded Dr Valenciano, adding that “the marginally missed non-inferiority criterion for the XBB.1.5 strain is not expected to be clinically meaningful. Adjuvanted RSVPreF3 co-administered with COVID-19 mRNA vaccine was well tolerated, with an acceptable reactogenicity and safety profile.”

Bonten M, et al. Co-administration of the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein vaccine (adjuvanted RSVPreF3) with a COVID-19 mRNA vaccine in ≥50-year-old adults. 6th ESCMID Vaccines, 10–13 September 2025, Lisbon, Portugal.

Medical Conferences

Adjuvanted RSVPreF3 can be co-administered with a COVID-19 mRNA vaccine in adults aged ≥50 years

Table of Contents: ESCMID Vaccines 2025

Featured articles

Letter from the Editor

Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years

ESCMID Vaccines 2025 Highlights Podcast

Pneumococcal Vaccination

A quarter of US children have incomplete pneumococcal vaccination by age 2

V116 shows promise for adults at risk of pneumococcal disease

Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years

The V116 pneumococcal vaccine is a new option in children at risk for pneumococcal disease

Influenza and COVID-19 Vaccination

Omicron XBB.1.5 vaccination provides effective, but rapidly waning protection in immunocompromised individuals

Intranasal COVID-19 vaccine shows promising results in preclinical mouse models

Influenza vaccine in children shows moderate, broad protection during the 2024-2025 season

Lower age is linked to reduced uptake of influenza and COVID-19 vaccination

RSV vaccination and Immunisation

Combination respiratory vaccines show promise but face key challenges

Adjuvanted RSVPreF3 demonstrates high real-world effectiveness in the USA

RSV immunisation: Maternal versus direct infant immunisation

European pregnant women show openness to maternal RSV vaccination

Infants immunised with nirsevimab have a lower risk of respiratory-related recurrent hospitalisation